Jun 2026 (Q1 FY27) — Aug 10, 2026
Mesa Laboratories Q1 FY27 — Strong Operational Turnaround and Deleveraging Progress
Read the full callMesa Laboratories (MLAB) earnings
- Jun 2026
- Jun 2026 (Q1 FY27)
- Mar 2026
Mesa Laboratories earnings: last reported Mon, 10 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 60.1 | +1.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 11.7 | +6.5 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 2.8 | −40.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$123.31 +0.68% · +$0.83
Performance +68.7% 1Y
1Y: $73.08 on 17 Oct 2025 → $123.31. High $142.23 (5 Oct 2026), low $70.6 (21 Nov 2025).
- Previous close
- $122.48
- 52-week range
- $70.6 – $142.23
- One year
- +61.32%
Overview
- Symbol
- MLAB
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Mesa Laboratories earnings calls (MLAB)
Financials
What the filings say
Net profit, year on year: −40% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 58 | 63 | 62 | 60 | 61 | 65 | 64 | 60 |
| Operating profit | 4 | 6 | 1 | 3 | 5 | 8 | 3 | 7 |
| Operating margin | 6.1% | 9.2% | 2.4% | 5.2% | 7.8% | 12.3% | 4.3% | 11.7% |
| Other income | 0 | -8 | -1 | 4 | -3 | -3 | -4 | -3 |
| Interest | 3 | 3 | — | 2 | 3 | 3 | 3 | 2 |
| Profit before tax | 4 | -2 | 0 | 7 | 2 | 5 | -2 | 4 |
| Tax rate | 10.1% | 24.4% | 1643.2% | 32.4% | −23.9% | 21.0% | −159.6% | 35.0% |
| Net profit | 3 | -2 | -7 | 5 | 2 | 4 | -4 | 3 |
| EPS ($ per share) | 0.63 | -0.31 | — | 0.87 | 0.45 | 0.66 | — | 0.50 |
| Line item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 40 | 158 | 318 | 313 | 332 | 344 | 359 | 375 |
| Reserves | 73 | 72 | 72 | 77 | 74 | -183 | -189 | -186 |
| Total liabilities | 45 | 189 | 195 | 314 | 268 | 301 | 274 | 242 |
| Fixed assets | 22 | 22 | 22 | 29 | 28 | 32 | 32 | 31 |
| Total assets | 157 | 409 | 601 | 707 | 662 | 447 | 433 | 428 |
| Line item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 31 | 27 | 37 | 39 | 28 | 44 | 47 | 43 |
| Cash from investing | -4 | -186 | -2 | -305 | -9 | -81 | -4 | -3 |
| Cash from financing | -22 | 231 | 146 | 53 | -33 | 33 | -45 | -42 |
| Net cash flow | 5 | 71 | 182 | -215 | -16 | -5 | -1 | -0 |
| Capital expenditure | -1 | -1 | -2 | -4 | -5 | -3 | -4 | -3 |
| Free cash flow | 29 | 25 | 35 | 35 | 23 | 42 | 43 | 40 |
Insider filings
32 filings between Oct 27, 2025 and Aug 15, 2026.
Open market
decisions to buy or sellPurchases
$1.35M
5 purchases by 4 insiders
Sales
$1.57M
7 sales by 4 insiders
43% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 3
- Award — granted as compensation
- 16
- Option exercise — converted options into shares
Also filed: 1 gift.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Kadia Siddhartha | $800.1K | — | Aug 13, 2026 |
| Sullivan John James | — | $800.1K | Aug 13, 2026 |
| Sakys John | — | $376.9K | Jun 22, 2026 |
| Archbold Brian David | — | $341.7K | Jun 22, 2026 |
| Ladiwala Shiraz Shabanali | $252.8K | — | Mar 10, 2026 |
| Tripeny R Tony | $202.3K | — | Aug 13, 2026 |
| Capone Mark Christopher | $99.3K | — | Mar 10, 2026 |
| Crennen Lyndsey Elizabeth | — | $51.5K | Jun 22, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 15, 2026 | Tripeny R Tony Director | Option exercise | 2,784 | $0 |
| Aug 15, 2026 | Hall Shannon Director | Option exercise | 2,784 | $0 |
| Aug 15, 2026 | Ladiwala Shiraz Shabanali Director | Option exercise | 3,810 | $0 |
| Aug 15, 2026 | Alltoft Jennifer Sadie Director | Option exercise | 2,784 | $0 |
| Aug 15, 2026 | Capone Mark Christopher Director | Option exercise | 2,784 | $0 |
| Aug 15, 2026 | Sullivan John James Director | Option exercise | 2,784 | $0 |
| Aug 13, 2026 | Tripeny R Tony Director | Purchase | 900 | $102.3K |
| Aug 13, 2026 | Kadia Siddhartha President and CEO | Purchase | 7,093 | $800.1K |
| Aug 13, 2026 | Sullivan John James Director | Sale | 7,093 | $800.1K |
| Jun 22, 2026 | Sakys John CFO | Sale | 2,827 | $253.0K |
| Jun 22, 2026 | Crennen Lyndsey Elizabeth CAO | Sale | 442 | $39.6K |
| Jun 22, 2026 | Archbold Brian David SVP Operations | Sale | 2,516 | $225.2K |
| Jun 18, 2026 | Archbold Brian David SVP Operations | Option exercise | 844 | $80.3K |
| Jun 18, 2026 | Crennen Lyndsey Elizabeth CAO | Option exercise | 125 | $11.9K |
| Jun 18, 2026 | Crennen Lyndsey Elizabeth CAO | Option exercise | 233 | $22.2K |
| Jun 18, 2026 | Crennen Lyndsey Elizabeth CAO | Option exercise | 368 | $35.0K |
| Jun 18, 2026 | Crennen Lyndsey Elizabeth CAO | Award | 263 | $25.0K |
| Jun 18, 2026 | Archbold Brian David SVP Operations | Award | 1,859 | $176.8K |
| Jun 18, 2026 | Sakys John CFO | Option exercise | 1,036 | $98.5K |
| Jun 18, 2026 | Sakys John CFO | Option exercise | 2,756 | $262.1K |
| Jun 18, 2026 | Sakys John CFO | Award | 2,282 | $217.0K |
| Jun 18, 2026 | Archbold Brian David SVP Operations | Option exercise | 2,480 | $235.8K |
| Jun 16, 2026 | Sakys John CFO | Sale 10b5-1 plan | 1,223 | $123.8K |
| Jun 16, 2026 | Crennen Lyndsey Elizabeth CAO | Sale 10b5-1 plan | 118 | $11.9K |
| Jun 16, 2026 | Archbold Brian David SVP Operations | Sale 10b5-1 plan | 1,151 | $116.6K |
| Jun 15, 2026 | Sakys John CFO | Option exercise | 2,717 | $282.8K |
| Jun 15, 2026 | Archbold Brian David SVP Operations | Option exercise | 2,454 | $255.4K |
| Mar 10, 2026 | Capone Mark Christopher Director | Purchase | 1,301 | $99.3K |
| Mar 10, 2026 | Ladiwala Shiraz Shabanali Director | Purchase | 3,500 | $252.8K |
| Mar 10, 2026 | Tripeny R Tony Director | Purchase | 1,315 | $99.9K |
| Dec 2, 2025 | Sullivan John James Director | Gift | 2,000 | $0 |
| Oct 27, 2025 | Owens Gary M President and CEO | Option exercise | 11,558 | $0 |
| Aug 15, 2025 | Alltoft Jennifer Sadie Director | Option exercise | 1,404 | $0 |
| Aug 15, 2025 | Capone Mark Christopher Director | Option exercise | 1,404 | $0 |
| Aug 15, 2025 | Tripeny R Tony Director | Option exercise | 1,404 | $0 |
| Aug 15, 2025 | Hall Shannon Director | Option exercise | 1,404 | $0 |
| Aug 15, 2025 | Sullivan John James Director | Option exercise | 1,404 | $0 |
| Aug 15, 2025 | Ladiwala Shiraz Shabanali Director | Option exercise | 1,949 | $0 |
| Jun 21, 2025 | Archbold Brian David SVP Operations | Option exercise | 844 | $80.9K |
| Jun 21, 2025 | Archbold Brian David SVP Operations | Tax withheld | 385 | $36.9K |
| Jun 21, 2025 | Sakys John CFO | Option exercise | 1,036 | $99.3K |
| Jun 21, 2025 | Sakys John CFO | Tax withheld | 454 | $43.5K |
| Jun 21, 2025 | Owens Gary M President and CEO | Option exercise | 3,301 | $316.3K |
| Jun 21, 2025 | Owens Gary M President and CEO | Tax withheld | 1,445 | $138.5K |
| Jun 18, 2025 | Archbold Brian David SVP Operations | Option exercise | 2,556 | $237.7K |
| Jun 18, 2025 | Archbold Brian David SVP Operations | Tax withheld | 1,166 | $108.4K |
| Jun 18, 2025 | Owens Gary M President and CEO | Option exercise | 8,707 | $809.7K |
| Jun 18, 2025 | Owens Gary M President and CEO | Tax withheld | 3,810 | $354.3K |
| Jun 18, 2025 | Sakys John CFO | Option exercise | 2,840 | $264.1K |
| Jun 18, 2025 | Sakys John CFO | Tax withheld | 1,243 | $115.6K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for MESA LABORATORIES INC /CO/
Free account. Everything above stays public.
Write why you follow MESA LABORATORIES INC /CO/ and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading